Table 2.
Cancer type-specific HER2 S310F, L755S, V777L, V842I, and L866M alterations that may predict response to a targeted drug and the corresponding OncoKB™ level of evidence assigning their level of clinical actionability. Level 2: Standard care biomarker recommended by the NCCN or other expert panels predictive of response to an FDA-approved drug in this indication. Level 3A: Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication but neither biomarker nor drug is standard of care.
| Cancer Type | Drug | Level |
|---|---|---|
| NSCLC | Ado-Trastuzumab Emtansine | 2 |
| NSCLC | Trastuzumab Deruxtecan | 2 |
| NSCLC | Neratinib | 3A |
| NSCLC | Trastuzumab + Pertuzumab + Docetaxel | 3A |
| Breast cancer | Neratinib | 3A |
Legend: NSCLC, non-small cell lung cancer.